| See the support offered with this hemophilia A treatment. |
View online |
|
|
|
|
| Esperoct® is indicated for on-demand treatment and control of bleeding episodes, perioperative bleed management, and routine prophylaxis in adults and children with hemophilia A. |
|
|
|
| Support for your patients—in person or virtually. |
| Whether you’re seeing hemophilia A patients in your office or for virtual visits, it’s great to be able to support their hemophilia journey. We have a wide range of resources and tools you can provide. |
|
|
|
|
|
| Scroll down to see some of our most popular patient support tools. |
 |
|
|
| Selected Important Safety Information |
| Contraindications |
| |
• |
Do not use in patients who have known hypersensitivity to Esperoct® or its
components, including hamster proteins
|
|
|
Warnings and Precautions
|
| |
• |
Hypersensitivity reactions, including anaphylaxis, may occur. Should
hypersensitivity reactions occur, discontinue Esperoct® and administer appropriate
treatment
|
|
|
Please
click here
or scroll below for additional Important Safety Information.
|
|
|
| Get your patients started. |
| Is Esperoct® the right fit for your patient? With our Trial Prescription Program, qualifying patients can receive 6 vials of Esperoct® at no charge.a |
|
|
|
| aPatients who have been prescribed a Novo Nordisk hemophilia and rare bleeding disorder product for an FDA-approved indication, and who have commercial insurance, may be eligible to receive a limited supply of free product. Patients who participate in any government, state, or federally funded medical or prescription benefit program, including Medicare, Medicaid, Medigap, VA, DOD, and TRICARE, including patients who participate in a managed Medicaid program or have Medicaid as secondary insurance, are not eligible to receive product support. Product is provided at no cost to the patient or the HCP, is not contingent on any product purchase, and the patient and HCP must not: (1) bill any third party for the free product, or (2) resell the free product. |
|
|
|
| Connect them with warm, personal support. |
| With NovoSecure™, your patients can connect one-on-one with an experienced specialist for help along their journey. Take a look at the benefits qualifying patients may receive. |
|
|
|
|
|
| Have you signed up for your Novo Nordisk account? |
 |
Keep up with important information about Esperoct® and other treatments. |
 |
Receive the latest product news and information from Novo Nordisk. |
 |
Download, order, and share patient educational materials. |
|
|
|
|
|
|
| Indications and Usage |
|
Esperoct® [antihemophilic factor (recombinant), glycopegylated-exei] is indicated
for use in adults and children with hemophilia A for on-demand treatment and control of bleeding
episodes, perioperative management of bleeding, and routine prophylaxis to reduce the frequency
of bleeding episodes
|
| |
• |
Esperoct® is not indicated for the treatment of von Willebrand
disease
|
|
|
Important Safety Information (cont’d)
|
| Warnings and Precautions |
| |
• |
Development of neutralizing antibodies (inhibitors) has occurred. Perform an assay
that measures Factor VIII inhibitor concentration if bleeding is not controlled with
the recommended dose of Esperoct® or if the expected plasma Factor
VIII activity levels are not attained
|
|
| Adverse Reactions |
| |
• |
The most frequently reported adverse reactions in clinical trials (≥1%) were
rash, redness, itching (pruritus), and injection site reactions
|
|
| Please click here for Prescribing Information. |
|
|
|
<%@ include view='hcpColoradoFooter' %>
|
| Please do not respond to this email. If you would like to contact us, please click here or call 1-800-727-6500. |
| UNSUBSCRIBE NOTICE |
| If you no longer want to receive communications from Novo Nordisk, click here to unsubscribe. You also may call us at 1-877-744-2579 or send us a letter that includes your full contact information (e.g. name, email address, phone) to Novo Nordisk, 800 Scudders Mill Road, Plainsboro, New Jersey 08536. To better understand how Novo Nordisk values your privacy, see our Privacy Statement. |
|
Esperoct® is a registered trademark and NovoSecure™ is a trademark of Novo Nordisk Health Care AG.
Novo Nordisk is a registered trademark of Novo Nordisk A/S.
© 2020 Novo Nordisk All rights reserved. US20ESP00053 September 2020 |
 |
|
|
|
